Sepsis patients.
Conditions
Interventions
Intervention 1: Intervention group: 100 mg of saffron in the form of a 100 mg tablet once a day for 7 days from Mojtahedi Commercial Company (transforming the powder into tablets will be done at the F
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Age between 18 and 80 years Consent of the patient or his legal guardian Digestive system with normal function and intestinal nutrition criteria Diagnosis of sepsis based on sepsis-3 criteria and confirmation anesthesiologist or infectious disease specialist.
Exclusion criteria
Exclusion criteria: Patient or his legal guardian dissatisfaction Patients who are hospitalized in the ICU for less than 48 hours or who cannot be fed enterally Patients who do not have an indication for enteral nutrition on the first day, and based on the diagnosis of the special care department, it is confirmed and predicted that they will not be able to receive enteral nutrition in the future. Patients who have cancer and are undergoing chemotherapy and taking cisplatin. Patients with congenital and immune disorders, kidney and liver failure, and pancreatitis. Patients taking anticonvulsants phenobarbital, Levetiracetam and phenytoin. Patients undergoing dialysis. Pregnancy and breastfeeding Septic shock or severe sepsis Patients expected to die within 2 days of admission to the ICU. Patients with BMI<18.5 kg/m2 Patients using other herbal supplements Allergy to herbal supplements or spices Patients with GCS levels less than 3 or more than 13
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| C reactive Protein (CRP). Timepoint: At baseline and end of the study. Method of measurement: ELISA test.;Erythrocyte sedimentation rate (ESR). Timepoint: At baseline and end of the study. Method of measurement: ELISA test.;Interleukin-6 (IL-6). Timepoint: At baseline and end of the study. Method of measurement: ELISA test.;Interleukin-18 (IL-18). Timepoint: At baseline and end of the study. Method of measurement: ELISA test.;Tumor necrosis factor-alpha (TNF-a). Timepoint: At baseline and end of the study. Method of measurement: ELISA test.;Lactate dehydrogenase (LDH). Timepoint: At baseline and end of the study. Method of measurement: Commercial enzymatic kit.;Total antioxidant capacity (TAC). Timepoint: At baseline and end of the study. Method of measurement: Commercial diagnostic kit.;Superoxide dismutase (SOD). Timepoint: At baseline and end of the study. Method of measurement: Commercial diagnostic kit.;Malondialdehyde (MDA). Timepoint: At baseline and end of the study. Method of measurement: Commercial diagnostic kit.;Glutathione peroxidase (GPx). Timepoint: At baseline and end of the study. Method of measurement: Commercial diagnostic kit.;Catalase. Timepoint: At baseline and end of the study. Method of measurement: Commercial diagnostic kit. | — |
Secondary
| Measure | Time frame |
|---|---|
| 28-day mortality rate. Timepoint: After 28 days of follow-up. Method of measurement: Mathematically dividing the number of dead people by the total number of people using hospital records or telephone follow-up.;Complete blood count (CBC). Timepoint: At baseline and end of the study. Method of measurement: Auto hematology analyzers.;Glasgow Coma Scale (GCS). Timepoint: At baseline and end of the study. Method of measurement: hospital records.;APACHE II Score. Timepoint: At baseline and end of the study. Method of measurement: hospital records.;SOFA score. Timepoint: At baseline and end of the study. Method of measurement: hospital records.;NUTRIC score. Timepoint: At baseline and end of the study. Method of measurement: hospital records.;Potassium. Timepoint: At baseline and end of the study. Method of measurement: Commercial diagnostic kit and the ion-selective electrode method.;Sodium. Timepoint: At baseline and end of the study. Method of measurement: Commercial diagnostic kit and the ion-selective electrode method.;Calcium. Timepoint: At baseline and end of the study. Method of measurement: Commercial diagnostic kit.;Magnesium. Timepoint: At baseline and end of the study. Method of measurement: Commercial diagnostic kit.;Chlorine. Timepoint: At baseline and end of the study. Method of measurement: Commercial diagnostic kit and the ion-selective electrode method.;Phosphorus. Timepoint: At baseline and end of the study. Method of measurement: Commercial diagnostic kit.;Blood Sugar. Timepoint: At baseline and end of the study. Method of measurement: Commercial diagnostic kit.;Alkaline Phosphatase. Timepoint: At baseline and end of the study. Method of measurement: Commercial diagnostic kit.;Alanine Aminotransferase. Timepoint: At baseline and end of the study. Method of measurement: Commercial diagnostic kit.;Aspartate Aminotransferase. Timepoint: At baseline and end of the study. Method of measurement: Commercial diagnostic kit.;Albumin. Timepoint: At baseline and | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Bagherniya
Esfahan University of Medical Sciences
Outcome results
None listed